Lead sponsor
Sanofi
10 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
10
Trials led
1
Ongoing
4,313
Total enrollment
257
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 1/2
1
Phase 2
6
Phase 3
2
Trials by status
Not yet recruiting
1
Completed
7
Terminated
1
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Completed1,455
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Completed1,306
Study of the Effect of SR57667B in Patients With Alzheimer's DiseaseAlzheimer's diseasePh 2Completed500
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's DiseaseStudy partner/caregiver requiredPh 2Completed390
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on DonepezilAlzheimer's diseasePh 2Completed291
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patientsmild-to-moderate ADPh 1Completed48
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's DiseaseAlzheimer's diseasePh 2Terminated1
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's DiseaseMCI due to ADPh 2Withdrawnnot disclosed